TRPC6 inhibition: The Visual Abstract

For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR, and was well tolerated. A new era in FSGS? Check out the visual abstract by Divya Bajpai